Home Cart Sign in  
Chemical Structure| 65473-14-5 Chemical Structure| 65473-14-5

Structure of Naftifine HCl
CAS No.: 65473-14-5

Chemical Structure| 65473-14-5

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Naftifine HCl is a broad-spectrum allylamine antifungal topically used to treat tinea pedis, tinea cruris, and tinea corporis (fungal infections).

Synonyms: Naftifine (hydrochloride); AW 105-843; Naftifine HCl

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Naftifine HCl

CAS No. :65473-14-5
Formula : C21H22ClN
M.W : 323.86
SMILES Code : CN(C/C=C/C1=CC=CC=C1)CC2=CC=CC3=CC=CC=C23.[H]Cl
Synonyms :
Naftifine (hydrochloride); AW 105-843; Naftifine HCl
MDL No. :MFCD00059047

Safety of Naftifine HCl

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
Rhodotorula mucilaginosa 0.1 mg/mL, 0.2 mg/mL 10 minutes To assess the effects of Naftifine on the growth and carotenoid synthesis of R. mucilaginosa. Results showed that Naftifine caused depigmentation of the colonies, which was reversible. PMC5593942
Human mycotic toenails 1% solution 3 hours To evaluate the penetration profile of Naftifine in toenails, results showed that Naftifine penetrated the entire toenail section within 3 hours but with lower concentrations in deeper layers. PMC11128420
T. tonsurans 0.03 to 0.12 μg/mL 4 days Evaluate the antifungal activity of naftifine hydrochloride against T. tonsurans, showing significant fungicidal effects. PMC3754295
T. mentagrophytes 0.03 to 1.0 μg/mL 4 days Evaluate the antifungal activity of naftifine hydrochloride against T. mentagrophytes, showing significant fungicidal effects. PMC3754295
Trichophyton rubrum 0.015 to 1.0 μg/mL 4 days Evaluate the antifungal activity of naftifine hydrochloride against Trichophyton rubrum, showing significant fungicidal effects. PMC3754295
Trichophyton mentagrophytes 0.04 mg/L 5 days To test the antifungal susceptibility of Naftifine against Trichophyton mentagrophytes, with a geometric mean MIC of 0.04 mg/liter. PMC8284460
Trichophyton interdigitale 0.06 mg/L 5 days To test the antifungal susceptibility of Naftifine against Trichophyton interdigitale, with a geometric mean MIC of 0.06 mg/liter. PMC8284460
Trichophyton indotineae 1.92 mg/L 5 days To test the antifungal susceptibility of Naftifine against Trichophyton indotineae, with a geometric mean MIC of 1.92 mg/liter. PMC8284460
Trichophyton rubrum 0.0312-16 μg/mL 5 days To evaluate the in vitro antifungal activity of Naftifine against Trichophyton rubrum, showing MIC range of 0.0312-16 μg/ml. PMC5923174
Trichophyton interdigitale 0.0312-16 μg/mL 5 days To evaluate the in vitro antifungal activity of Naftifine against Trichophyton interdigitale, showing MIC range of 0.0312-16 μg/ml. PMC5923174
Trichophyton mentagrophytes 0.125–4 µg/ml 72 hours Evaluate the in vitro antifungal activity of Naftifine against Trichophyton mentagrophytes, showing MIC50 of 0.5 µg/ml and MIC90 of 2 µg/ml PMC7674369

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Wistar albino rats Tinea infection model Topical administration 12.5 mg Once daily for 14 days To evaluate the antifungal and anti-inflammatory effects of Naftifine in the treatment of Tinea. The results showed that the optimized formulation exhibited good antifungal and anti-inflammatory activity, achieving up to 2-, 3-, 5.75-, and 2.74-fold increases in the amount of permeated NF, steady-state flux, permeability, and diffusion coefficients, respectively, compared with a commercial product. PMC8725874

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT00750139 Tinea Pedis A... More >>thlete's Foot Less << Phase 3 Completed - United States, Alabama ... More >> Radiant Research Birmingham, Alabama, United States, 35209 United States, California Dr. Felix Sigal Los Angeles, California, United States, 90010-3209 University of California San Francisco, Dept of Dermatology San Francisco, California, United States, 94115 United States, Florida FXM Research Miami, Florida, United States, 33175 FXM Research Miramar, Florida, United States, 33027 United States, Illinois Glazer Dermatology Buffalo Grove, Illinois, United States, 60089 United States, Louisiana Tulane University Health Services New Orleans, Louisiana, United States, 70112 United States, Michigan Silverton Skin Institute Grand Blanc, Michigan, United States, 48439 United States, North Carolina Zoe Draelos, MD High Point, North Carolina, United States, 27262 United States, Ohio Haber Dermatology Euclid, Ohio, United States, 44118 United States, Oregon Oregon Dermatology and Research Center Portland, Oregon, United States, 97210 United States, Pennsylvania Paddington Testing Company Philadelphia, Pennsylvania, United States, 19103 Temple University School of Podiatric Medicine Philadelphia, Pennsylvania, United States, 19107 United States, South Carolina Coastal Carolina Research Center Mt. Pleasant, South Carolina, United States, 29464 United States, Texas J & S Studies College Station, Texas, United States, 77845 Research Across America Dallas, Texas, United States, 75234 Research Across America Plano, Texas, United States, 75093 Less <<
NCT00253305 Onychomycosis Phase 2 Completed - United States, Alabama ... More >> University of Alabama at Birmingham Birmingham, Alabama, United States, 35233 United States, Arizona Genova Clinical Research, Inc. Tucson, Arizona, United States, 85741 United States, Florida Greater Miami Skin and Laser Center Miami Beach, Florida, United States, 33140 United States, Missouri Washington University St. Louis, Missouri, United States, 63110 United States, Oregon Northwest Cutaneous research Portland, Oregon, United States, 97210 Less <<
NCT02658292 Tinea Capitis Phase 2 Withdrawn - -
NCT01289015 - Completed - -
NCT01712360 Tinea Pedis T... More >>inea Cruris Less << Phase 4 Completed - United States, Texas ... More >> Merz Investigative Site #001272 Austin, Texas, United States, 78759 Merz Investigative Site #001261 College Station, Texas, United States, 77802 Dominican Republic Merz Investigative Site #180001 Santo Domingo, Dominican Republic Honduras Merz Investigative Site #504001 San Pedro Sula, Honduras Less <<
NCT01290341 Tinea Pedis Phase 3 Completed - -
NCT01290341 - Completed - -
NCT01712360 - Completed - -
NCT02227290 Tinea Corporis Phase 4 Completed - United States, Arizona ... More >> Merz Investigative Site#001316 Tucson, Arizona, United States, 85712 United States, California Investigative Site# 0010320 Encino, California, United States, 91436 Merz Investigative Site#001313 Fremont, California, United States, 94538 Merz Investigative Site#001301 San Diego, California, United States, 92102 United States, Florida Merz Investigative Site#001312 Miami, Florida, United States, 33144 Merz Investigative Site#001311 Miami, Florida, United States, 33175 Merz Investigative Site #001310 Miramar, Florida, United States, 33027 United States, Missouri Merz Investigative Site#001307 Saint Joseph, Missouri, United States, 64506 United States, Nebraska Merz Investigative Site#001309 Omaha, Nebraska, United States, 68114 United States, Nevada Merz Investigative Site#001314 Henderson, Nevada, United States, 89074 United States, North Carolina Merz Investigative Site#001126 Raleigh, North Carolina, United States, 27612 Merz Investigative Site#001293 Winston Salem, North Carolina, United States, 27104 United States, Oregon Investigative Site# 0010319 Gresham, Oregon, United States, 97030 United States, Tennessee Merz Investigative Site#001097 Nashville, Tennessee, United States, 37215 Dominican Republic Merz Investigative Site#180002 San Cristobal, Dominican Republic Merz Investigative Site# 180001 Santo Domingo, Dominican Republic Honduras Merz Investigative Site#504001 San Pedro Sula, Honduras Panama Merz Investigative Site#507001 Panama City, Panama Puerto Rico Merz Investigative Site#001279 Cidra, Puerto Rico, 00739 Less <<
NCT01580891 Tinea Pedis Phase 1 Completed - -
NCT01885156 Tinea Cruris ... More >>Jock Itch Less << Phase 3 Completed - Belize ... More >> Merz Investigational Site # 501001 Belize City, Belize Merz Investigational Site # 501002 Belize City, Belize Dominican Republic Merz Investigative Site # 180002 San Cristobal, Dominican Republic Merz Investigative Site # 180001 Santo Domingo, Dominican Republic Honduras Merz Investigative Site # 504001 San Pedro Sula, Honduras Less <<
NCT02466867 Tinea Corporis Phase 4 Completed - United States, Texas ... More >> Merz Investigative Site#001261 College Station, Texas, United States, 77845 Dominican Republic Merz Investigative Site#180001 Santo Domingo, Dominican Republic Honduras Merz Investigative Site #504001 San Pedro Sula, Honduras Less <<
NCT01289015 Tinea Pedis Phase 3 Completed - -
NCT02132260 Tinea Pedis Phase 1 Completed - -
NCT00750139 - Completed - -
NCT02633813 Tinea Pedis Phase 3 Completed - United States, Florida ... More >> Moore Clinical Research Inc Brandon, Florida, United States, 33511 Savin Medical Group Research Miami, Florida, United States, 33014 International Dermatology Research, Inc, Miami, Florida, United States, 33144 FXM Research Corp Miami, Florida, United States, 33175 FXM Research Miramar Miramar, Florida, United States, 33027 South Tampa, MOORE Clinical Research, Inc. Tampa, Florida, United States, 33609 North Tampa MOORE Clinical Research, Inc. Tampa, Florida, United States, 33618 United States, Missouri Medi Search Saint Joseph, Missouri, United States, 64506 United States, Texas Bellaire Dermatology Associates Bellaire, Texas, United States, 77401 Research Across America Dallas, Texas, United States, 75234 Family Practise Mesquite, Texas, United States, 75149 Research Across America Plano, Texas, United States, 75093 Dominican Republic Instituto Dermatológico y Cirugía de Piel Santo Domingo, San Cristóbal, Dominican Republic, 91000 Instituto Dermatológico Barrio Maria Auxiliadora, Santo Domingo, Dominican Republic, 10305 Less <<
NCT02335255 Tinea Pedis Phase 1 Completed - -

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

3.09mL

0.62mL

0.31mL

15.44mL

3.09mL

1.54mL

30.88mL

6.18mL

3.09mL

References

 

Historical Records

Categories